Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36
The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative.
The webcast of Mr. Plesha’s presentation will be available at:
The presentation will also be located under “News & Events” in the Investors section of the Company’s website. A replay of the webcast will be available on the Pelthos’ website for 90 days following the presentation.
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat Molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at .
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Lower Oil Prices
09:12 AM EDT, 10/06/2026 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Tuesday's premarket activity amid lower oil prices and optimism around tech stocks. US stock futures were also higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.7%, and Nasdaq futures gaining 0.7% before the start of regular trading. The US international trade deficit widened to $105.57 billion in August from a $92.83 billion gap in July, compared with a $102.1 billion gap expected in a survey compiled by Bloomberg as of 7:35 am ET. In premarket activity, bitcoin was up by 0.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1% higher, Ether ETF (EETH) advanced 1.6%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat. Power Play: Health Care The State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.3%, while the Vanguard Health Care Index Fund (VHT) and the iShares US Healthcare ETF (IYH) were inactive. The iShares Biotechnology ETF (IBB) was 0.7% higher. Option Care Health (OPCH) shares were up 21% pre-bell Tuesday after McKesson (MCK) and CD&R agreed to buy the company for roughly $5.80 billion. Winners and Losers: Technology The State Street Technology Select Sector SPDR ETF (XLK) gained 0.7%, the iShares US Technology ETF (IYW) was 0.5% higher, and the iShares Expanded Tech Sector ETF (IGM) was inactive. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was inactive, while the iShares Semiconductor ETF (SOXX) rose by 0.5%. Xanadu Quantum Technologies (XNDU) shares were up 7% in premarket activity after the company entered a multiyear deal with GlobalFoundries (GFS). GlobalFoundries was 1.4% higher. Financial The State Street Financial Select Sector SPDR ETF (XLF) advanced 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.9%, while its bearish counterpart, Direxion Daily Financial Be
Iran Tries to Oust Diplomat Who Met Trump Envoys: Will It Reverse Oil Price Slide?
EasyA Co-Founder Phil Kwok Drops Bombshell Statement for XRP Army
CENOVUS ENERGY INCORPORATION <CVE.TO>: RAYMOND JAMES RAISES TARGET PRICE TO C$53 FROM C$51
CENOVUS ENERGY INCORPORATION : RAYMOND JAMES RAISES TARGET PRICE TO C$53 FROM C$51
Crypto prices
More
